Navigation Links
ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Date:2/5/2009

SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext US: ANX), announced today that it has completed patient enrollment in its bioequivalence study of ANX-514 (docetaxel emulsion for injection). The Company is on track to announce results from this study in the second quarter of 2009.

ANX-514 is a reformulation of the blockbuster chemotherapeutic agent, Taxotere(R), an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate, head and neck & gastric cancers. In 2007, the aggregate worldwide market for Taxotere was in excess of $3 billion.

The study is a multi-center, open-label, randomized two-period crossover comparison of ANX-514 and Taxotere, with a primary endpoint of pharmacokinetic equivalence of ANX-514 and Taxotere and a goal of 28 evaluable patients. The safety of a single dose of ANX-514 is being evaluated as a secondary endpoint. The U.S. Food and Drug Administration has indicated that this single study, should it demonstrate bioequivalence between ANX-514 and Taxotere, would provide sufficient human data to support the submission of an NDA.

About ANX-514 (docetaxel emulsion)

ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
2. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
3. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
5. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
7. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
8. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
9. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Calif. , May 23, 2013 More ... cancer may not benefit from chemotherapy and still have ... the launch of one of the largest sources of ... new website and interactive Facebook page provide recently diagnosed ... they can safely avoid chemotherapy. "We anticipate ...
(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC.  ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...
(Date:5/23/2013)... Texas , May 23, 2013  Texas, premier ... to deliver doctors the survival tools they need to ... compete in today,s health care marketplace. "I ... will save local practices," said Stephen L. ... Association (TMA). " Texas doctors are ...
Breaking Medicine Technology:Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
... Qmed .com , the world,s only 100% ... engine, and central industry resource, today announced a ... ground-breaking detailed reports of industry-related adverse events, ... http://photos.prnewswire.com/prnh/20120423/LA91769LOGO )   (Logo: http://photos.prnewswire.com/prnh/20101214/LA16070LOGO ...
... BEACH, Fla., April 23, 2012  SurgLine International, Inc. ... International, Inc. ("SGLN") and SurgLine, Inc. ("SurgLine") stated ... SurgLine has formed SurgLine MDC Holdings, LLC. ("SMDC"), ... owned subsidiary.  SMDC will be forming  joint-venture opportunities ...
Cached Medicine Technology:Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events 2Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events 3Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events 4SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies 2
(Date:5/23/2013)... May 23, 2013 Live ... contemporary services, provides the best business lead solution ... Its Call center Management solution features Free Web ... Call Limitation, Do-Not-Call Maintenance and "Automatic Transfer Retry". ... comprehensive campaign delivery and management system. , Its ...
(Date:5/23/2013)... drug about to be tested in a clinical trial ... treatment for Alzheimer,s disease has failed to work with ... patients, according to results of a study by University ... of neuroscience affiliated with the Evelyn F. and William ... emphasized the importance of verifying promising research results before ...
(Date:5/23/2013)... poor prognosis, with limited treatment options. In some ... it,s supposed to. New research from Western University explains ... identifies a mechanism to rectify that. ... team at Western,s Schulich School of Medicine & Dentistry, ... the death of cancer cells by binding to and ...
(Date:5/23/2013)... New York, New York (PRWEB) May 23, 2013 ... products manufactured by C.R. Bard, Inc., continue to move ... District Court, Southern District of West Virginia, Bernstein Liebhard ... 17th, the Court denied a request by C.R. Bard ... claimed would reveal trade secrets and other confidential, proprietary ...
(Date:5/23/2013)... 2013 Former United States Vice President ... Acadian 's annual Paramedic Luncheon. , In front ... Cheney praised Acadian's medics, saying, "I am delighted to ... awarding the Paramedic of the Year Award. I think ... lot of competition within a company like this because ...
Breaking Medicine News(10 mins):Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2
... which is ill-equipped to cope, say experts. The amount of ... and rising, suggests health data. ,India has a population of ... developing diabetes later in life, and are certainly more vulnerable ... coronary heart disease. ,Part of the blame falls ...
... is bad for health. ,It seems that smokers have a ... heart disease in their blood. The discovery could help explain ... attacks than non-smokers. ,Paraoxonase is a enzyme which ... blood vessels. A team of Swiss researchers examined 367 people ...
... weapons go, anthrax is nowhere as terrifying as several others, ... University. Smallpox would be a lot worse. The government now ... Experiments are getting underway to see whether it can be ... still be effective. // ,“Anthrax is not ...
... less than 1mm in diameter, presents a new opportunity for ... Hollywood film technicians who worked alongside Dr Nicolas Beechey-Newham and ... at Guy’s Hospital in London to produce the “micro-camera”. ... the opening in a nipple – is able to view ...
... efficacy of a malaria drug are being questioned by ... be withdrawn. Manufacturer GlaxoSmithKline markets the anti-malarial drug Malarone ... at preventing the aggressive falciparum strain of malaria, but ... the Consumers’ Association – says the evidence for this ...
... be more likely to create illness than the weapons themselves, ... result of panic caused by the news of anthrax attacks. ... the UK, US and Australia predicted that while bioweapons themselves ... is having a devastating effect. ,Already, there are ...
Cached Medicine News:Health News:Diabetes on the rise, 2Health News:All the more bad, 2